Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

Imagine yourself as a passive income investor looking for a medical stock with significant share growth potential. Wall ...

Merck posted strong Q4 earnings, with a 7% revenue increase to $15.62 billion, beating expectations. Growth was driven by ...

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

We recently compiled a list of the 12 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are ...

Adding Winrevair to standard pulmonary arterial hypertension (PAH) treatment is generally safe and effective, a pooled trial ...

Sales of new pulmonary arterial hypertension drug, Winrevair, also missed estimates. The decline in Merck’s stock price post-earnings has left investors confused about whether to buy ...

I also want to point out the excellent news related to Winrevair (sotatercept), which is, in turn, the flagship of Merck's cardiovascular franchise. On January 30 of this year, it announced that ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – pembrolizumab -, Merck’s anti-PD-1 therapy, for ...

Feb 25 (Reuters) - Drugmaker Merck (MRK.N), opens new tab said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become ...